Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
WM-3835 is an inhibitor of lysine acetyltransferase 6A (KAT6A) and KAT7 (IC50s = 17 and 30 nM, respectively).1 It is selective for KAT6A and KAT7 over KAT5 (IC50 = 312 nM). WM-3835 (1 µM) reduces the viability of primary mouse leukemia stem cells (LSCs), MOLM-13 and OCI-AML-3 acute myeloid lymphoma (AML) cells, as well as decreases colony formation in patient-derived primary AML cells. It induces cell cycle arrest at the sub-G1 phase and apoptosis, as well as decreases the levels of mRNA encoding homeobox protein A7 (HOXA7), in MOLM-13 cells. In vivo, WM-3835 (5 mg/kg per day) reduces tumor volume, weight, and growth rate, as well as decreases the acetylation at lysine 14 on histone 3 (H3K14), H3K12, and H3K5 in tumor cell lysates, in a PPC-1 prostate cancer mouse xenograft model.2
WARNING This product is not for human or veterinary use.
1. HBO1 is required for the maintenance of leukaemia stem cells. Nature 577(7789), 266-270 (2020).
2. A first-